Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart Inc. (VXRT) is a clinical-stage biotechnology company pioneering oral tablet vaccines for infectious diseases. This page aggregates official announcements, financial disclosures, and scientific developments related to its recombinant vaccine platform and clinical pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, manufacturing updates, and peer-reviewed research findings – all essential for evaluating Vaxart's position in the competitive vaccine market.
Key content focuses on tablet vaccine efficacy data, FDA communications, intellectual property developments, and comparative analyses of mucosal immunization approaches. Bookmark this page to monitor Vaxart's progress in redefining vaccine administration through its temperature-stable oral delivery system.
Vaxart (NASDAQ: VXRT), a clinical-stage biotech company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 5, 2025, at 2:00 PM ET. The event will be accessible via live webcast on Vaxart's website, with a replay available for 30 days after the event. Investors seeking meetings with management during the conference should contact their Jefferies representative.
Vaxart (NASDAQ: VXRT) has released a video update from Founder and CSO Dr. Sean Tucker, urging stockholders to vote in favor of Proposal No. 2 for a reverse stock split. The proposal aims to help Vaxart regain compliance with Nasdaq's minimum bid price requirement. Stockholders of record as of March 26, 2025, must cast their votes by 11:59 p.m. Eastern Time on June 1, 2025. The company has also provided a fact sheet addressing common misconceptions about the reverse split proposal. Shareholders who previously voted against the proposal can change their vote, and assistance is available through Campaign Management, LLC.
Vaxart (NASDAQ: VXRT) has announced the adjournment of its 2025 annual stockholders meeting to June 2, 2025 at 8:30 a.m. Pacific Time. The virtual meeting will address all proposals from the proxy statement filed on April 10, 2025. The company is particularly focused on gaining stockholder approval for Proposal No. 2 regarding a Reverse Stock Split, which aims to regain Nasdaq compliance for minimum bid price requirements. The Board argues this split would help maintain Nasdaq listing, increase broker/analyst coverage, attract institutional investors, and aid in employee retention. Stockholders of record as of March 26, 2025, can vote until June 1, 2025 at 11:59 p.m. Eastern Time.
Vaxart (NASDAQ: VXRT) announced equity inducement awards for its new Chief Financial Officer, Jeroen Grasman, effective May 19, 2025. The compensation package includes: (1) an option to purchase 1,000,000 shares of common stock, vesting 25% after one year and 1/48th monthly thereafter, with exercise price at grant date closing price, and (2) a restricted stock unit (RSU) award of 350,000 shares, vesting 25% annually over four years. The awards were granted under Vaxart's 2024 Inducement Award Plan, complying with Nasdaq Listing Rule 5635(c)(4) for new employee inducement awards.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
